roginolisib

Phase 2Small molecule

IiOnctura

roginolisib is one of 189 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

188

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

LymphomaActive, not recruiting

Uveal MelanomaActive, not recruiting

MyelofibrosisActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Myelofibrosis，mfRecruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Uveal MelanomaPhase 2

Active, not recruiting

MyelofibrosisPhase 1/Phase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1/Phase 2

Active, not recruiting

Myelofibrosis，mfPreclinical

Recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

roginolisib

IiOnctura

Phase 2

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Norvir

AbbVie

Preclinical

1 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

PEG-Intron

Merck & Co.

Preclinical

1 7

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 8

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

2 9

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

2 10

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Active, not recruiting

Lung Cancer

NCT06879717

Q3 2028

PreclinicalRecruiting

Myelofibrosis，mf

NCT06887803

Q4 2028

Phase 2Active, not recruiting

Uveal Melanoma

NCT06717126

Q4 2029

Phase 1Recruiting

Uveal Melanoma

NCT07203391

Clinical

Trials by Indication[1]

Uveal Melanoma2 trials

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

Active, not recruiting·IiOnctura·Phase 2·NCT06717126·85 enrolled

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

Recruiting·SSt Vincent's Hospital, Sydney·Phase 1·NCT07203391·8 enrolled

Lymphoma1 trial

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 1/2·NCT07018752·49 enrolled

Chronic Lymphocytic Leukemia1 trial

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Recruiting·—·Phase 1/2·NCT06644183·64 enrolled

Lung Cancer1 trial

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

Active, not recruiting·IiOnctura·Phase 1/2·NCT06879717·45 enrolled

Myelofibrosis，MF1 trial

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to an Approved JAK Inhibitors (HEMA-MED)

Recruiting·IiOnctura·Preclinical·NCT06887803·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for roginolisib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — roginolisib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for roginolisib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — iOnctura company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IiOnctura

roginolisib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Uveal Melanoma2 trials

Lymphoma1 trial

Chronic Lymphocytic Leukemia1 trial

Lung Cancer1 trial

Myelofibrosis，MF1 trial

References

Drug Info

Quick Facts

Related News